EVC2 Inhibitors

EVC2 inhibitors comprise a range of compounds that influence EVC2 either directly or indirectly by targeting specific cellular pathways and molecular processes. Sorafenib, a RAF kinase inhibitor, modulates EVC2 indirectly through the RAF/MEK/ERK signaling cascade. This disrupts downstream pathways, altering the expression and function of EVC2 and influencing cellular processes related to its regulation. Y-27632, a Rho kinase inhibitor, indirectly influences EVC2 by disrupting Rho/ROCK signaling. This alteration in downstream pathways impacts EVC2 expression and function, illustrating the intricate network of cellular interactions involved in EVC2 regulation. Similarly, SP600125 inhibits the JNK pathway, indirectly modulating EVC2 by affecting downstream signaling cascades that influence its expression and function. AZD8055, a mTOR inhibitor, disrupts mTORC1 and mTORC2 complexes, indirectly influencing EVC2 expression and function through downstream pathway modulation. Dasatinib, a Src family kinase inhibitor, affects EVC2 indirectly by disrupting downstream signaling pathways, showcasing the interconnected nature of cellular processes related to EVC2 regulation. LY294002, a PI3K inhibitor, modulates EVC2 indirectly by disrupting the PI3K/AKT pathway, altering downstream signaling cascades that impact EVC2 expression and function. SB-203580 inhibits p38 MAPK signaling, indirectly influencing EVC2 by disrupting the phosphorylation of p38 MAPK and affecting downstream pathways related to EVC2 regulation. Erlotinib, an EGFR inhibitor, influences EVC2 indirectly by disrupting EGFR signaling, altering downstream pathways that impact EVC2 expression and function. Bortezomib, a proteasome inhibitor, indirectly affects EVC2 by disrupting proteasome function, altering protein degradation pathways related to EVC2 regulation. Cisplatin induces DNA damage, activating signaling pathways that modulate EVC2 expression and function. TAK-733 inhibits MEK/ERK signaling, indirectly influencing EVC2 by targeting MEK and disrupting downstream pathways. MK-2206, an Akt inhibitor, modulates EVC2 indirectly by disrupting the PI3K/AKT pathway, altering downstream signaling cascades that impact EVC2 expression and function.